RxDoctor Payments Data

Elizabeth Naman

Family · Mobile, ALNPI 1912655887

Payments from drug & device makers

$2,980in general payments, 2019–2025

Across 123 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • AbbVie$350
  • Coloplast$322
  • Baxter Healthcare$195
  • Medtronic$191
  • AstraZeneca$118
  • plus $719 from 17 others

What the payments were for

  • Speaking & faculty fees$1254%
  • Travel & lodging$50%
  • Food & beverage$2,85096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,980 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$61,872
Medicare patients
332
Services billed
3,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron310$219,742
MyrbetriqMirabegron123$74,615
Estradiol411$28,601
Methenamine Hippurate283$19,333
Solifenacin Succinate187$8,621
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst204$3,917
Tolterodine Tartrate ErTolterodine Tartrate24$2,247
Trospium Chloride ErTrospium Chloride12$1,676
Trospium Chloride15$1,229
Trimethoprim32$1,190
Cefdinir64$996
NitrofurantoinNitrofurantoin Macrocrystal13$425
Tamsulosin Hcl21$272
Fluconazole40$190
Doxycycline Hyclate14$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,085$219,742310 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.

Other family in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →